Metabolon Expands Targeted Assay Services to Support Pharmaceutical R&D
RESEARCH TRIANGLE PARK, N.C. – August 10, 2017 – Metabolon, Inc., the global leader in metabolomics, now offers more than 150 qualified and/or validated targeted biochemical assays for pharmaceutical and biotechnology R&D. These assays focus on specific metabolites or metabolic pathways and can be used to track biomarkers and enhance biological understanding across preclinical and clinical research.
Developed biomarker assays reflect the evolution of global metabolomics and are excellent tools to rapidly and accurately establish pharmacodynamics and monitor efficacy and safety in clinical trials. The role of biomarkers is also expanding to inform new therapeutic indications and disease targets, patient segmentation and novel mechanisms of action. Interested parties can register here to participate in a free webinar highlighting the value of targeted biochemical assays on Tuesday, August 15, 2017, at 11am EDT.
“Metabolomics is becoming a staple in studies of individual health, disease and treatment response,” said Mike Milburn, PhD, Chief Scientific Officer at Metabolon. “The biomarkers that emerge from ongoing research will ultimately produce tests that improve clinical trial assessment, disease management and patient care. Metabolon is pleased to announce expanded targeted assay solutions to support pharmaceutical and biotechnology partners in their mission to develop safe, effective medicines. We have a diverse selection of internally developed assays, as well as the ability to develop custom assays to meet research and clinical trial needs.”
Pharmaceutical and biotechnology researchers increasingly encounter metabolite biomarkers related to target biology or therapeutic effect and seek to use these findings to guide the drug development process.
“We recognize that increasing constraints on resources are pushing researchers to seek reliable partners to conduct biomarker assays for clinical trials,” continued Milburn. “We’re meeting that need based on a deep understanding of the clinical relevance of metabolites as biomarkers in disease and treatment, technology advances, and the limitations of legacy methods used in metabolite analysis, such as ELISA or IHC. Our technology and expertise can have significant, positive impact throughout the clinical development process.”
LC-MS/MS-based assays can be customized based on client needs and developed under the quality system for research use only (RUO) or validated under Good Clinical Practice (GCP) and Clinical Laboratory Improvement Amendments (CLIA).
Metabolon’s pre-developed targeted assays include:
- Fatty acid metabolism panel
- Short-chain fatty acid panel
- Bile acid panel
- Cholesterol metabolism panel
- Stratum corneum panel
- Sebum lipid panel
- accuGFR™ panel (to estimate glomerular filtration rate)
- 7 alpha-hydroxy-4-cholesten-3-one (C4) panel
- Metal ion panel
Metabolomics is the study of small molecules called metabolites and is a powerful phenotyping technology for life sciences research, population health and precision medicine. It measures changes in metabolite levels and maps them to the appropriate biochemical pathways to give researchers and clinicians a better understanding of health and the influences of genes, microbiome, diet, lifestyle and drug treatment.
Metabolon’s Precision Metabolomics™ technology screens the largest, most diverse metabolite library in the industry and uses its proprietary software to deliver the most accurate and comprehensive metabolomics data available. This data is a cornerstone in precision medicine and is currently being used by clinicians and life sciences researchers to gain immediately actionable information and understand genomic and other ‘omics data.
Metabolon, Inc. is the world’s leading health technology company advancing metabolomics for precision medicine and all areas of life sciences research. Its Precision Metabolomics is a powerful, patented technology for assessing health and delivering biomarker discoveries, innovative diagnostic tests, and valuable data in genomics and population health initiatives. Metabolon’s expertise is also accelerating research and product development across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations. The company was founded in 2000 and is based in Research Triangle Park, North Carolina. For more information, please visit www.metabolon.com or follow us on LinkedIn or Twitter.
Cautionary Note about Forward-Looking Statements
The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties and assumptions. If any of these risks or uncertainties materialize, or if any of these assumptions prove to be incorrect, Metabolon’s results could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; the clinical utility of Metabolon’s metabolomic services; Metabolon’s and its distributors’ ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including access, pricing and reimbursement of diagnostic tests; the strength of Metabolon’s intellectual property portfolio; Metabolon’s history of operating losses; whether Metabolon is able to achieve or sustain profitability; its highly competitive industry; its ability to compete effectively; security and privacy risks; and Metabolon’s ability to continue to innovate and provide products and services that are useful to its clients, among other risks, uncertainties and assumptions.
Vice President, Corporate Communications & Investor Relations